Publications
The researchers said their findings offer the potential for
the natural regulation of insulin and a significant reduction in
diabetes-related complications such as blindness and limb amputation. The study is published in the the
journal Cell.
More work needed for treatment to work
Although the hormone shows promise in lab mice, much more work is needed before it could be considered as a treatment for diabetes in humans, the researchers noted. Results obtained in animal experiments often aren't attainable in trials with humans.
"If this could be used in people, it could eventually mean that instead of taking insulin injections three times a day, you might take an injection of this hormone once a week or once a month, or in the best case maybe even once a year," Doug Melton, co-director of the institute and co-chair of Harvard University's department of stem cell and regenerative biology, said in a university news release.
Miilions living with diabetes
About 26 million Americans have type 2 diabetes, which causes people to slowly lose beta cells and the ability to produce sufficient amounts of insulin.
"Our idea here is relatively simple," Melton said. "We would provide this hormone, the type 2 diabetic will make more of their own insulin-producing cells, and this will slow down, if not stop, the progression of their diabetes. I've never seen any treatment that causes such an enormous leap in beta cell replication."
Along with its potential for treating type 2 diabetes, betatrophin might also have a role in treating type 1 diabetes, Melton said.
